Abstract: The disclosure provides a pharmaceutical composition containing an anti-IgE antibody that suppresses the production of allergen-specific IgE antibodies and methods of use thereof.

Abstract: The disclosure provides a pharmaceutical composition containing an anti-IgE antibody that suppresses the production of allergen-specific IgE antibodies and methods of use thereof.

Abstract: The disclosure provides a pharmaceutical composition containing an anti-IgE antibody that suppresses the production of allergen-specific IgE antibodies and methods of use thereof

Abstract: Polypeptides, polynucleotides, fragments thereof, and monoclonal antibodies thereto are provided for antigen-specific and antigen-non-specific glycosylation inhibiting factor and a method for recombinant production of biologically active polypeptides from a structural gene encoding the polypeptide.

Abstract: Antigen non-specific human glycosylation inhibiting factor derivatives having the inmunosuppressive activity in which a mutation was introduced for replacement, deletion and/or insertion of a part of the amino acid sequence of SEQ ID NO:21, and/or which has received a chemical modification of one or more amino acid residue(s) in the amino acid sequence of SEQ ID NO:21, wherein the mutation and the chemical modification attenuate the strength of an intermolecular association in the region, which participates in trimerization, of an antigen non-specific human glycosylation inhibiting factor having the amino acid sequence of SEQ ID NO:21; DNAs containing a base sequence encoding the amino acid sequence of the antigen non-specific human glycosylation inhibiting factor derivative; recombinant vectors containing the DNAs; prokaryotic or eukaryotic cells transformed with the DNAs; methods of producing the antigen non-specific human glycosylation inhibiting factor derivatives; pharmaceutical compositions comprising t

Abstract: A method for the recombinant production and for the isolation of antigen-specific glycosylation inhibiting factor (AgGIF) is provided. Also disclosed is a method for modulating the immune responses in an antigen-specific manner utilizing a AgGIF, comprising soluble non-specific GIF-TCR.alpha. chains which bind to the antigen, and which suppress the immune response in an antigen-specific fashion.

Abstract: Polypeptides, polynucleotides, fragments thereof, and monoclonal antibodies thereto are provided for antigen-specific and antigen-non-specific glycosylation inhibiting factor and a method for recombinant production of biologically active polypeptides from a structural gene encoding the polypeptide.

Abstract: The present invention provides antigen-specific human glycosylation inhibiting factor (GIF), Hybridoma cell lines ATCC HB 10473 and 11052 are provided as exemplary cell lines which produce human antigen-specific human GIF, directed toward honey bee venom and cedar pollen, respectively.

Abstract: The present invention provides antigen-specific human glycosylation inhibiting factor (GIF) and a method for immunosuppression of a specific immune response. Preferably, the antigen-specific GIF is directed toward an allergen. Hybridoma cell lines, ATCC HB 10472 and 10473, are provided as exemplary cell lines which produce human antigen-specific human glycosylation inhibiting factor directed toward cedar pollen and honey bee venom allergen, respectively.

Abstract: Plasmid vectors are provided that carry complementary DNA (cDNA) clones coding for polypeptides exhibiting mammalian IgE binding factor activity. One of these clones contains an open reading frame consisting of 556 codons. The cDNA is derived from messenger RNA isolated from a rat/mouse T-cell hybridoma line. The cDNA was cloned by incorporation into a pcD plasmid vector. The plasmid vector also contains DNA segments from the SV40 virus, permitting expression of the cDNA to form a polypeptide having IgE potentiating activity after transfection into a mammalian host cell, such as monkey Cos7 cells.